Galectin Therapeutics (GALT) Stock is Set To Gap-Up: Here is Why

The action during the premarket trading period often gives a fair idea of the way the market is going to go for the rest of the day and this morning, the Galectin Therapeutics Inc (NASDAQ: GALT) stock has emerged as a notable gainer.

The stock has surged by 27% this morning and the rise is possibly linked to a major announcement made by the company yesterday. Galectin announced yesterday that a paper published in the noted medical journal named Journal for ImmunoTherapy of Cancer described the results from the Phase 1 clinical study of one of the company’s projects.

Related:  Penny Revive Therapeutics (RVVTF) To Break $1 Ceiling On More Than 50 Million Shares

The study is a joint effort from Galectin and the Providence Cancer Institute that operated out of Portland in Oregon. The results were positive and the publication of the same in the highest-ranked journal with regards to open access immunology is a significant boost for Galectin. Investors could consider keeping track of this stock today.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.